KITE-197
- Generic Name
- KITE-197
Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma
Phase 1
Recruiting
- Conditions
- Relapsed/Refractory Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 39
- Registration Number
- NCT06079164
- Locations
- 🇺🇸
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Henry-Joyce Cancer Clinic, Nashville, Tennessee, United States
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
Phase 2
- Conditions
- Solid and Hematological Malignancies
- Interventions
- Biological: Anitocabtagene autleucel
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 1000
- Registration Number
- NCT05041309
- Locations
- 🇫🇷
Centre Hospitalier Regional Universitaire de Lille, Lille, France
🇫🇷Hospital Saint Eloi, Montpellier CEDEX 05, France
🇫🇷Hopital Saint-Louis, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath